
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2576841/publications.pdf Version: 2024-02-01



SHENCU RL

#	Article	IF	CITATIONS
1	Changing Epidemiology of Hepatitis A in China: Evidence From Three National Serological Surveys and the National Notifiable Disease Reporting System. Hepatology, 2021, 73, 1251-1260.	3.6	16
2	Dual-Antigen-Loaded Hepatitis B Virus Core Antigen Virus-like Particles Stimulate Efficient Immunotherapy Against Melanoma. ACS Applied Materials & Interfaces, 2020, 12, 53682-53690.	4.0	20
3	Complete genome analysis of hepatitis B virus in Qinghai-Tibet plateau: the geographical distribution, genetic diversity, and co-existence of HBsAg and anti-HBs antibodies. Virology Journal, 2020, 17, 75.	1.4	5
4	Preparation and preliminary evaluation of hepatitis B core antigen virus like nanoparticles loaded with indocyanine green. Annals of Translational Medicine, 2020, 8, 1661-1661.	0.7	3
5	Theranostic Quercetin Nanoparticle for Treatment of Hepatic Fibrosis. Bioconjugate Chemistry, 2019, 30, 2939-2946.	1.8	22
6	Hepatitis E outbreak in a mechanical factory in Qingdao City, China. International Journal of Infectious Diseases, 2019, 86, 191-196.	1.5	13
7	Bioengineered Nanocage from HBc Protein for Combination Cancer Immunotherapy. Nano Letters, 2019, 19, 1719-1727.	4.5	40
8	Design of Fusion Proteins for Efficient and Soluble Production of Immunogenic Ebola Virus Glycoprotein in <i>Escherichia coli</i> . Biotechnology Journal, 2018, 13, 1700627.	1.8	5
9	Modularized peptides modified HBc virus-like particles for encapsulation and tumor-targeted delivery of doxorubicin. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 725-734.	1.7	45
10	Investigation of the risk factors associated with the failure of hepatitis B vaccination of neonates in Yunnan province, China. International Journal of Infectious Diseases, 2018, 77, 90-95.	1.5	6
11	Intranasal vaccination with ebola virus GP amino acids 258–601 protects mice against lethal challenge. Vaccine, 2018, 36, 6053-6060.	1.7	8
12	Improved Stable Indocyanine Green (ICG)â€Mediated Cancer Optotheranostics with Naturalized Hepatitis B Core Particles. Advanced Materials, 2018, 30, e1707567.	11.1	123
13	CD8 + T-Cell Response-Associated Evolution of Hepatitis B Virus Core Protein and Disease Progress. Journal of Virology, 2018, 92, .	1.5	12
14	Intranasal inoculate of influenza virus vaccine against lethal virus challenge. Vaccine, 2018, 36, 4354-4361.	1.7	13
15	Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China. Emerging Infectious Diseases, 2017, 23, 765-772.	2.0	241
16	Whole-gene analysis of two groups of hepatitis B virus C/D inter-genotype recombinant strains isolated in Tibet, China. PLoS ONE, 2017, 12, e0179846.	1.1	5
17	Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. Science Translational Medicine, 2016, 8, 329ra33.	5.8	78
18	An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates. Journal of Infectious Diseases, 2016, 214, S326-S332.	1.9	28

#	Article	IF	CITATIONS
19	Construction and Immunological Evaluation of CpC-Au@HBc Virus-Like Nanoparticles as a Potential Vaccine. Nanoscale Research Letters, 2016, 11, 338.	3.1	35
20	Epitope-based recombinant diagnostic antigen to distinguish natural infection from vaccination with hepatitis A virus vaccines. Journal of Virological Methods, 2016, 233, 41-45.	1.0	6
21	Protective effect of enterovirus-71 (EV71) virus-like particle vaccine against lethal EV71 infection in a neonatal mouse model. Molecular Medicine Reports, 2015, 12, 2473-2480.	1.1	12
22	Full-length genome characterization and quasispecies distribution of hepatitis A virus isolates in China. Virology Reports, 2015, 5, 29-46.	0.4	3
23	Enhanced Mucosal Immune Responses Induced by a Combined Candidate Mucosal Vaccine Based on Hepatitis A Virus and Hepatitis E Virus Structural Proteins Linked to Tuftsin. PLoS ONE, 2015, 10, e0123400.	1.1	17
24	The long-term efficacy, 13–23 years, of a plasma-derived hepatitis B vaccine in highly endemic areas in China. Vaccine, 2015, 33, 2704-2709.	1.7	21
25	Risk factors of hepatitis C virus transmission and genotype distribution in former blood donors from Chinese rural area. BMC Public Health, 2015, 15, 184.	1.2	13
26	The long-term efficacy of Chinese hamster ovary cell derived hepatitis B vaccine after being used for 14–16 years in Chinese rural communities. Vaccine, 2015, 33, 294-297.	1.7	6
27	Efficient Encapsulation of Fe ₃ O ₄ Nanoparticles into Genetically Engineered Hepatitis B Core Virusâ€Like Particles Through a Specific Interaction for Potential Bioapplications. Small, 2015, 11, 1190-1196.	5.2	59
28	lmmune Responses to HBsAg Conjugated to Protein D of Non-Typeable Haemophilus influenzae in Mice. PLoS ONE, 2015, 10, e0117736.	1.1	4
29	Epidemiology of Hepatitis E Virus in China: Results from the Third National Viral Hepatitis Prevalence Survey, 2005–2006. PLoS ONE, 2014, 9, e110837.	1.1	41
30	Multiplex Hydrolysis Probe Real-Time PCR for Simultaneous Detection of Hepatitis A Virus and Hepatitis E Virus. International Journal of Molecular Sciences, 2014, 15, 9780-9788.	1.8	7
31	Molecular epidemiological study of hepatitis B virus genotypes in Southwest, China. Journal of Medical Virology, 2014, 86, 1307-1313.	2.5	14
32	High expression of small hepatitis D antigen in Escherichia coli and ELISA for diagnosis of hepatitis D virus. Journal of Virological Methods, 2014, 197, 34-38.	1.0	4
33	Development of a sandwich ELISA for the quantification of enterovirus 71. Cytotechnology, 2014, 66, 413-418.	0.7	7
34	Construction and immunological evaluation of truncated hepatitis B core particles carrying HBsAg amino acids 119–152 in the major immunodominant region (MIR). Biochemical and Biophysical Research Communications, 2013, 439, 84-89.	1.0	4
35	Reprint of: Epidemiological serosurvey of Hepatitis B in China—Declining HBV prevalence due to Hepatitis B vaccination. Vaccine, 2013, 31, J21-J28.	1.7	117
36	Change in Hepatitis B Virus Large Surface Antigen Variant Prevalence 13 Years after Implementation of a Universal Vaccination Program in China. Journal of Virology, 2013, 87, 12196-12206.	1.5	50

#	Article	IF	CITATIONS
37	Comparative evaluation of a novel TaqMan real-time reverse transcription–polymerase chain reaction assay for hepatitis A virus detection. Journal of International Medical Research, 2013, 41, 427-434.	0.4	3
38	Prevalence of Human Parvovirus B19, Bocavirus, and PARV4 in Blood Samples from the General Population of China and Lack of a Correlation between Parvovirus and Hepatitis B Co-Infection. PLoS ONE, 2013, 8, e64391.	1.1	12
39	Genetic Diversity of Hepatitis A Virus in China: VP3-VP1-2A Genes and Evidence of Quasispecies Distribution in the Isolates. PLoS ONE, 2013, 8, e74752.	1.1	14
40	Hepatitis C virus-specific cellular and humoral immune responses following immunization with a multi-epitope fusion protein. International Journal of Molecular Medicine, 2012, 29, 12-7.	1.8	3
41	Prevalence and risk factors of hepatitis C among former blood donors in rural China. International Journal of Infectious Diseases, 2012, 16, e731-e734.	1.5	14
42	Efficacy of yeast-derived recombinant hepatitis B vaccine after being used for 12 years in highly endemic areas in China. Vaccine, 2012, 30, 6623-6627.	1.7	16
43	Development of a hepatitis delta virus antibody assay for study of the prevalence of HDV among individuals infected with hepatitis B virus in China. Journal of Medical Virology, 2012, 84, 445-449.	2.5	16
44	Genotyping of acute hepatitis a virus isolates from China, 2003–2008. Journal of Medical Virology, 2011, 83, 1134-1141.	2.5	12
45	Distribution and Hepatocellular Carcinoma–Related Viral Properties of Hepatitis B Virus Genotypes in Mainland China: A Community-Based Study. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 777-786.	1.1	90
46	Neuraminidase and Hemagglutinin Matching Patterns of a Highly Pathogenic Avian and Two Pandemic H1N1 Influenza A Viruses. PLoS ONE, 2010, 5, e9167.	1.1	27
47	General Epidemiological Parameters of Viral Hepatitis A, B, C, and E in Six Regions of China: A Cross-Sectional Study in 2007. PLoS ONE, 2009, 4, e8467.	1.1	92
48	Evaluation of the Impact of Hepatitis B Vaccination among Children Born during 1992–2005 in China. Journal of Infectious Diseases, 2009, 200, 39-47.	1.9	301
49	Hepatitis A outbreaks in China during 2006: application of molecular epidemiology. Hepatology International, 2009, 3, 356-363.	1.9	34
50	HCV envelope protein function is dependent on the peptides preceding the glycoproteins. Biochemical and Biophysical Research Communications, 2009, 378, 118-122.	1.0	15
51	Hepatitis C virus envelope glycoproteins complementation patterns and the role of the ecto- and transmembrane domains. Biochemical and Biophysical Research Communications, 2009, 385, 257-262.	1.0	10
52	Hemagglutinin and neuraminidase matching patterns of two influenza A virus strains related to the 1918 and 2009 global pandemics. Biochemical and Biophysical Research Communications, 2009, 387, 405-408.	1.0	22
53	Generation of neutralizing monoclonal antibodies against Enterovirus 71 using synthetic peptides. Biochemical and Biophysical Research Communications, 2009, 390, 1126-1128.	1.0	42
54	Oseltamivir boosts 2009 H1N1 virus infectivity in vitro. Biochemical and Biophysical Research Communications, 2009, 390, 1305-1308.	1.0	15

#	Article	IF	CITATIONS
55	Epidemiological serosurvey of Hepatitis B in China—Declining HBV prevalence due to Hepatitis B vaccination. Vaccine, 2009, 27, 6550-6557.	1.7	813
56	Efficient neutralizing activity of cocktailed recombinant human antibodies against hepatitis a virus infection in vitro and in vivo. Journal of Medical Virology, 2008, 80, 1171-1180.	2.5	7
57	Hepatitis B virus precore protein augments genetic immunizations of the truncated hepatitis C virus core in BALB/c mice. Hepatology, 2007, 47, 25-34.	3.6	15
58	Proteomic Fingerprints for Potential Application to Early Diagnosis of Severe Acute Respiratory Syndrome. Clinical Chemistry, 2005, 51, 56-64.	1.5	69
59	The Structural Characterization and Antigenicity of the S Protein of SARS-CoV. Genomics, Proteomics and Bioinformatics, 2003, 1, 108-117.	3.0	3
60	The E Protein Is a Multifunctional Membrane Protein of SARS-CoV. Genomics, Proteomics and Bioinformatics, 2003, 1, 131-144.	3.0	41
61	The Structure Analysis and Antigenicity Study of the N Protein of SARS-CoV. Genomics, Proteomics and Bioinformatics, 2003, 1, 145-154.	3.0	24
62	Complete Genome Sequences of the SARS-CoV: the BJ Group (Isolates BJ01-BJ04). Genomics, Proteomics and Bioinformatics, 2003, 1, 180-192.	3.0	15
63	The R Protein of SARS-CoV: Analyses of Structure and Function Based on Four Complete Genome Sequences of Isolates BJ01-BJ04. Genomics, Proteomics and Bioinformatics, 2003, 1, 155-165.	3.0	1
64	Application of two RNA extraction methods prior to amplification of hepatitis E virus nucleic acid by the polymerase chain reaction. Journal of Virological Methods, 1991, 35, 331-342.	1.0	53